You just read:

BerGenBio Completes Recruitment Into First Stage of Phase II Breast Cancer Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA®

News provided by

BerGenBio ASA

19 Feb, 2018, 07:31 GMT